1. Home
  2. EYE vs SNDX Comparison

EYE vs SNDX Comparison

Compare EYE & SNDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo National Vision Holdings Inc.

EYE

National Vision Holdings Inc.

HOLD

Current Price

$27.98

Market Cap

2.0B

Sector

Health Care

ML Signal

HOLD

Logo Syndax Pharmaceuticals Inc.

SNDX

Syndax Pharmaceuticals Inc.

HOLD

Current Price

$21.21

Market Cap

1.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
EYE
SNDX
Founded
1990
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Ophthalmic Goods
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.0B
1.7B
IPO Year
2017
2016

Fundamental Metrics

Financial Performance
Metric
EYE
SNDX
Price
$27.98
$21.21
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
9
12
Target Price
$27.11
$36.92
AVG Volume (30 Days)
1.3M
1.6M
Earning Date
11-05-2025
11-03-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$1,921,355,000.00
$111,304,000.00
Revenue This Year
$9.80
$620.14
Revenue Next Year
$4.50
$115.42
P/E Ratio
N/A
N/A
Revenue Growth
6.33
595.65
52 Week Low
$9.93
$8.58
52 Week High
$29.87
$22.73

Technical Indicators

Market Signals
Indicator
EYE
SNDX
Relative Strength Index (RSI) 50.49 64.62
Support Level $27.70 $19.72
Resistance Level $29.45 $22.73
Average True Range (ATR) 1.12 0.91
MACD -0.18 -0.05
Stochastic Oscillator 24.29 59.94

Price Performance

Historical Comparison
EYE
SNDX

About EYE National Vision Holdings Inc.

National Vision Holdings Inc is an optical retailer in the U.S. Its product portfolio includes eyeglasses and sunglasses, contact lenses, accessories, and other products. The company has two operating segments; Owned and Host segment includes company-owned brands America's Best and Eyeglass World, In America's Best stores, vision care services are provided by optometrists or by independent professional corporations and Host operating consist of Military and Fred Meyer which provide eye exams by independent optometrists, and the Legacy segment manages the operations of, and supplies inventory and lab processing services to Legacy retail Vision Centers. It earns a majority of its revenue from the Owned and Host segment.

About SNDX Syndax Pharmaceuticals Inc.

Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.

Share on Social Networks: